Pathologic Complete Response After Preoperative Ipilimumab and Nivolumab in an HLRCC Patient with Stage III RenalCell Carcinoma. (2026). Journal of Kidney Cancer, 13(2), 21-28. https://doi.org/10.15586/jkcvhl.v13i2.455